Immunological, Mental and Physical After-effects of COVID-19 infectio

Recruiting

• Conditions: COVID19; infection with SARSCoV2; 10047438

• Registration Number: NL-OMON55044
• Lead Sponsor: OLVG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 450

Inclusion Criteria

all patients who visited the postCOVID outpatient clinic in the OLVG 3 months
after their COVID19 infection

Exclusion Criteria

none

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>recovery of quality of life based on the results of questionnaires after<br /><br>COVID19 infection</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. occurrence of new infections with SARSCoV2 within year after admission with<br /><br>COVID19 infection, based on self-report, confirmed with (patient approved)<br /><br>requested information about the confirmation of that infection in another<br /><br>laboratory<br /><br><br /><br>2.outcomes of lung function studies in patients who still had an impaired lung<br /><br>function test after 3 months and who are being followed up at the outpatient<br /><br>clinic for lung diseases at 6, 12 and 18-24 months after COVID19 infection<br /><br><br /><br>3.occurrence of death within a year after COVID19 infection and record of cause<br /><br>of death (retrieved via GP, with prior patient consent)<br /><br><br /><br>4.height of concentration of antibodies against SARSCoV2 at 6 and 12 months<br /><br>after admission with COVID19 infection</p><br>